

# AIDS Vaccine Research Status

**Carl W. Dieffenbach, Ph.D.**  
**Director, Division of AIDS**  
**National Institute of Allergy and**  
**Infectious Diseases**

March 25, 2008



# Summit—Setting a New Direction

---

- **NIAID is seeking input on the entire HIV vaccine research endeavor, including (but not limited to):**
  - **Optimal balance between discovery and development**
  - **NHP model development, optimization and utilization**
  - **Integration of clinical research with discovery**

# Summit—Setting a New Direction

---


- **NIAID will work toward implementing key recommendations from this summit**
  - **This summit is a step in building an ongoing, more effective dialogue with the scientific community**
- **How will we implement the recommendations from the summit?**

# Maintaining the Pay Line -- The Balance between RO1s and Targeted Initiatives

---

**Initiatives**

**Unsolicited  
RO1s**



# HIV Vaccine Discovery Grants

---

- **All meritorious, solicited HIV vaccine discovery grant applications were funded in FY 2007**
- **Looking forward, there is a need for new/novel ideas**
- **Need mechanisms to support new investigators**
- **We can only fund ideas that are submitted**

# Current HIV Vaccine Discovery Efforts at NIAID

---

- Unsolicited grants
- Innovation grant program
- HIV Vaccine Research and Design Program (HIVRAD)
- Center for HIV/AIDS Vaccine Immunology (CHAVI)

# Current HIV Vaccine Development Efforts at NIAID

---

- Integrated Preclinical Clinical AIDS Vaccine Development Program (IPCAVD)
- HIV Vaccine Design and Development Teams (TEAMS)
- Preclinical Master Contract

# **Current Efforts that Support HIV Vaccine Discovery and Development**

---

- Simian Vaccine Evaluation Units (SVEU)
- HIV Vaccine Trials Network (HVTN)



# **New HIV Vaccine Discovery Efforts at NIAID**

---

- **Increasing involvement of B-cell immunologists**
  - FY07 ‘jump start’; 9 supplements; \$1.5M
  - FY08 RFA; ~11 awards pending; ~\$4.3M
- **Highly Innovative Tactics to Interrupt Transmission (HIT-IT)**
  - Targeted for FY09 awards

# **Future HIV Vaccine Discovery**

---

- **Set the optimal balance between discovery and development**
- **NIAID will use targeted initiatives and select pay to bolster HIV vaccine discovery research**
- **The amount of funds committed to this will depend on the availability of funds and the quality of the science that is proposed**
- **The source of funds will vary, including the redirection of money from ongoing HIV development activities**

# Animal Models


---

- **Are a critical part of vaccine discovery**
- **Provide valuable information on the potential immunogenicity and efficacy of vaccine concepts**
- **They can be used to:**
  - **Prioritize and/or reject specific designs;**
  - **Optimize vaccine designs before moving into development**
  - **Suggest potential immune correlates to be explored in human trials**
- **NIAID seeks input on how best to address the impediments to the effective use of this valuable research tool**

# Clinical Research

---

- **Clinical research is essential to understand HIV infection providing information that can only be obtained in humans**
- **How can we optimize the use of the NIAID supported clinical capacity?**
- **How can collaboration and communication across the spectrum of vaccine research be improved?**



# Critical Elements for Success

- New and innovative ideas
- Creative ways of supporting and evaluating new concepts
- An improved atmosphere of collaboration and cooperation
- Open and constructive discussion and transparent decision-making processes
- Clear criteria for product development
- Learning from concept failures

**Safe and  
Effective  
HIV  
Vaccine**

# **Panels to Foster Discussion Today**

---

- **Balance between discovery and development enhancing discovery research**
- **NHP model development, optimization and utilization**
- **Integration of clinical research with discovery**